Antibiotics for community-acquired pneumonia
Matthew Dryden1, Kieran Hand, Peter Davey
1Department of Microbiology and Communicable Disease, Royal Hampshire County Hospital, Winchester, UK. matthew.dryden@wehct.nhs.uk
The Journal of Antimicrobial Chemotherapy
|October 13, 2009
Summary
For severe community-acquired pneumonia (CAP), using narrow-spectrum antibiotics can be as effective as broad-spectrum ones. This approach minimizes antibiotic resistance and superinfections, reducing collateral damage.
Area of Science:
- Infectious Diseases
- Pharmacology
- Public Health
Background:
- Current antibiotic guidelines for community-acquired pneumonia (CAP) often suggest broad-spectrum agents for severe cases.
- Over-prescription of broad-spectrum antibiotics carries risks, including collateral damage such as superinfections by resistant pathogens and the selection of antibiotic resistance.
- Narrow-spectrum agents can be equally effective with fewer adverse consequences.
Purpose of the Study:
- To evaluate the risks and benefits of broad-spectrum versus narrow-spectrum antibiotic prescribing for severe community-acquired pneumonia (CAP).
- To advocate for updated antibiotic guidance that prioritizes narrow-spectrum agents when appropriate, even in severe CAP cases.
Main Methods:
- Review of existing literature and clinical guidelines on antibiotic treatment for CAP.
- Analysis of the spectrum of activity, efficacy, and potential for collateral damage associated with different antibiotic classes.
- Assessment of the impact of antibiotic selection on the development of resistance and superinfections.
Main Results:
- Broad-spectrum antibiotics, while effective, increase the risk of collateral damage, including antibiotic resistance and superinfections.
- Narrow-spectrum antibiotics demonstrate comparable efficacy in many severe CAP cases.
- Reduced collateral damage is associated with the judicious use of narrow-spectrum agents.
Conclusions:
- Antibiotic guidelines should be revised to encourage the use of narrow-spectrum agents for severe CAP when clinically appropriate.
- Promoting narrow-spectrum prescribing can mitigate the development of antibiotic resistance and reduce patient harm.
- Optimizing antibiotic selection is crucial for effective CAP management and public health preservation.
Related Concept Videos
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: